Engineering small-molecule analogues of altiratinib via CREB-regulated transcription co-activator 3-target screening for the development of potent and safe topical therapeutics against skin hyperpigmentary diseases

Jeong Hyeon Lee; Hongchan An; HyeJi Kwon; Su-Jeong Lee; Young Hye Park; Ji Sun Hwang; Min Young Kim; Hayoung Hwang; Jeong Yoon Kim; Seung Jin Lee; Sung Eun Chang; Youngsup Song

doi:10.1002/ctm2.1625

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (3) : e1625 DOI: 10.1002/ctm2.1625

LETTER TO THE JOURNAL

Engineering small-molecule analogues of altiratinib via CREB-regulated transcription co-activator 3-target screening for the development of potent and safe topical therapeutics against skin hyperpigmentary diseases

Author information +

History +

PDF

Cite this article

Download citation ▾

Jeong Hyeon Lee, Hongchan An, HyeJi Kwon, Su-Jeong Lee, Young Hye Park, Ji Sun Hwang, Min Young Kim, Hayoung Hwang, Jeong Yoon Kim, Seung Jin Lee, Sung Eun Chang, Youngsup Song. Engineering small-molecule analogues of altiratinib via CREB-regulated transcription co-activator 3-target screening for the development of potent and safe topical therapeutics against skin hyperpigmentary diseases. Clinical and Translational Medicine, 2024, 14(3): e1625 DOI:10.1002/ctm2.1625

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Yoo H, Lee HR, Kim KH, et al. CRTC3, a sensor and key regulator for melanogenesis, as a tunable therapeutic target for pigmentary disorders. Theranostics. 2021;11(20):9918-9936.

[2]	Nguyen NT, Fisher DE. MITF and UV responses in skin: from pigmentation to addiction. Pigment Cell Melanoma Res. 2019;32(2):224-236.

[3]	Yasumoto K, Yokoyama K, Shibata K, Tomita Y, Shibahara S. Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene. Mol Cell Biol. 1994;14(12):8058-8070.

[4]	Bang S, Won KH, Moon HR, et al. Novel regulation of melanogenesis by adiponectin via the AMPK/CRTC pathway. Pigment Cell Melanoma Res. 2017;30(6):553-557.

[5]	Solano F, Briganti S, Picardo M, Ghanem G. Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res Dec. 2006;19(6):550-571.

[6]	Smith BD, Kaufman MD, Leary CB, et al. Altiratinib inhibits tumor growth, invasion, angiogenesis, and microenvironment-mediated drug resistance via balanced inhibition of MET, TIE2, and VEGFR2. Mol Cancer Ther. 2015;14(9):2023-2034.

[7]	Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165-169.

[8]	Kumari S, Carmona AV, Tiwari AK, Trippier PC. Amide bond bioisosteres: strategies, synthesis, and successes. J Med Chem. 2020;63(21):12290-12358.

[9]	Nakano S, Abe Y, Nakajima K, et al. Establishment of a mouse model for post-inflammatory hyperpigmentation. Pigment Cell Melanoma Res. 2021;34(1):101-110.

[10]	Luo L, Patel A, Sinko B, et al. A comparative study of the in vitro permeation of ibuprofen in mammalian skin, the PAMPA model and silicone membrane. Int J Pharm. 2016;505(1-2):14-19.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.